Molecules 2019, 24, 3451
6 of 10
1
4-one (12, 481.4 mg, 73%). H-NMR (300 MHz, DMSO)
δ
8.62 (dd, J = 1.4 Hz, J = 4.7 Hz, 1H), 8.34 (dd,
J = 1.4 Hz, J = 8.1 Hz, 1H), 7.76 (dd, J = 4.7 Hz, J = 8.1 Hz, 1H), 7.64 (d, J = 2.1 Hz, 1H), 7.57 (d, J = 1.5
Hz, 1H), 7.47 (s, 1H), 2.54 (s, 3H), 1.71 (s, 3H); 13C-NMR (126 MHz, DMSO)
δ
157.7, 148.6, 147.7, 145.5,
140.5, 140.3, 139.9, 136.3, 135.8, 134.3, 128.5, 127.9, 127.3, 120.5, 117.8, 112.5, 15.8, 14.3.
3-Bromo-1-(3-chloropyridin-2-yl)-N-(2-methyl-6-(methylcarbamoyl)-4-(methylthio)phenyl)-1H-
pyrazole-5-carboxamide (14)
To a solution of 2-(3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl)-8-methyl-6-(methylthio)-4H-
benzo[d][1,3]oxazin-4-one (12, 400 mg, 0.862◦6 mmol) in THF (1.5 mL) was adde◦d methylamine solution
(2.0 M in THF, 1.4 mL, 2.8465 mmol) at 0 C. The mixture was stirred at 0 C for 5 h, the mixture
was extracted with EtOAc (200 mL). The organic layer was dried over anhydrous Na2SO4, filtered
and evaporated. The resulting crude residue was purified by column chromatography on silica gel
(CH2Cl2/MeOH, 20:1) to give 3-bromo-1-(3-chloropyridin-2-yl)-N-(2-methyl-6-(methylcarbamoyl)-4-
(methylthio)phenyl)-1H-pyrazole-5-carboxamide (14, 263.4 mg, 62%). mp. 247 ◦C; LC/MS: Rt = 2.82
mins, m/z (ES-) = 494 (M + H for C19H17BrClN5O2S); IR (KBr):
1024, 958, 878, 861, 801, 794, 761 cm−1; 1H-NMR (300 MHz, CDCl3)
J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.17 (s, 1H), 7.05 (s, 2H), 6.26 (s, 1H), 2.92 (d, J = 3.1 Hz, 3H), 2.43 (s, 3H),
2.14 (s, 3H); 13C-NMR (126 MHz, DMSO)
167.0, 155.5, 148.3, 147.0, 139.5, 139.1, 136.8, 136.6, 134.6,
ν
1654, 1633, 1540, 1535, 1459, 1344, 1311,
δ
10.00 (s, 1H), 8.45 (s, 1H), 7.83 (d,
δ
129.3, 128.6, 127.7, 126.7, 126.5, 122.5, 110.4, 26.0, 17.7, 14.5; HRMS (EI) calcd for C19H17BrClN5O3S
494.9975, found 494.9949.
3-Bromo-1-(3-chloropyridin-2-yl)-N-(2-methyl-4-(S-methyl-N-(2,2,2-trifluoroacetyl)sulfinimidoyl)-
6-(methylcarbamoyl)phenyl)-1H-pyrazole-5-carboxamide (15a) and 3-bromo-1-(3-chloropyridin-2-yl)-
N-(2-methyl-6-(methylcarbamoyl)-4-(methylsulfinyl)phenyl)-1H-pyrazole-5-carboxamide (15b)
To a solution of 3-bromo-1-(3-chloropyridin-2-yl)-N-(2-methyl-6-(methylcarbamoyl)-4-(methylthio)
phenyl)-1H-pyrazole-5-carboxamide (14, 50 mg, 0.1014 mmol) in dried CH2Cl2 (1 mL) was added
trifluoroacetamide (22.92 mg, 0.2028 mmol), magnesium oxide (16.35 mg, 0.4056 mmol), Rh◦odium(II)
acetate (2.2 mg, 0.005 mmol), and iodobenzene diacetate (49 mg, 0.1521 mmol) at 0 C. After
stirring at room temperature for 13 h, the reaction mixture was extracted with CH2Cl2 (100 mL).
The organic layer was dried over anhydrous Na2SO4, filtered, and evaporated. The resulting
crude residue was purified by column chromatography on silica gel (CH2Cl2/MeOH, 20:1) to give
3-bromo-1-(3-chloropyridin-2-yl)-N-(2-methyl-4-(S-methyl-N-(2,2,2-trifluoroacetyl)sulfinimidoyl)-6-
(methylcarbamoyl)phenyl)-1H-pyrazole-5-carboxamide (15a, 17.9 mg, 29%) and 3-bromo-1-(3-
chloropyridin-2-yl)-N-(2-methyl-6-(methylcarbamoyl)-4-(methylsulfinyl)phenyl)-1H-pyrazole-5-
carboxamide (15b, 11.3 mg, 22%). 15a: mp. 199–200 ◦C; IR (KBr):
1266, 1183, 1145, 962, 801 cm−1; 1H-NMR (500 MHz, CDCl3)
10.70 (s, 1H), 8.43 (d, J = 4.6 Hz, 1H),
7.85 (d, J = 8.0 Hz, 1H), 7.72 (s, 1H), 7.65 (s, 1H), 7.37 (dd, J = 4.7 Hz, J = 8.0 Hz, 1H), 7.14 (s, 1H), 6.93
(d, J = 4.7 Hz, 1H), 2.94 (d, J = 4.7 Hz, 3H), 2.86 (s, 3H), 2.24 (s, 3H); 13C-NMR (125 MHz, CDCl3)
ν 1635, 1535, 1465, 1413, 1354, 1302,
δ
δ
166.0, 164.6 (q, CF3CO, J = 33.4 Hz), 155.4, 148.2, 147.0, 139.2, 139.1, 138.2, 136.6, 135.5, 131.2, 130.3,
127.7, 126.8, 126.5, 124.6, 116.8 (q, CF3, J = 289.8 Hz), 110.8, 32.8, 26.0, 17.9; 19F NMR (470 MHz, CDCl3)
δ
-73.28 ppm; HRMS (EI) calcd for C21H17BrClF3N6O3S 603.9907, found 603.9898. 15b: mp. 155 ◦C; IR
(KBr):
CDCl3)
J = 1.7 Hz, 1H), 7.38 (dd, J = 4.7 Hz, J = 8.0 Hz, 2H), 7.09 (s, 1H), 6.70 (d, J = 4.7 Hz, 1H), 2.97 (d, J = 4.8
Hz, 3H), 2.67 (s, 3H), 2.27 (s, 3H); 13C-NMR (125 MHz, CDCl3)
168.3, 155.7, 149.0, 146.9, 143.0, 139.0,
ν
1654, 1636, 1533, 1459, 1355, 1344, 1297, 1241, 1041, 1024, 959, 797 cm−1; 1H NMR (500 MHz,
10.64 (s, 1H), 8.46 (dd, J = 1.5 Hz, J = 4.7 Hz, 1H), 7.85 (dd, J = 1.5 Hz, J = 8.0 Hz, 1H), 7.71 (d,
δ
δ
138.9, 137.7, 136.8, 130.2, 129.0, 128.3, 128.3, 125.8, 119.6, 111.0, 44.0, 26.9, 19.6; HRMS (EI) calcd for
C19H17BrClN5O3S 508.9924, found 508.9893.
3-Bromo-1-(3-chloropyridin-2-yl)-N-(2-methyl-4-(S-methyl-N-(2,2,2-trifluoroacetyl)sulfonimidoyl)
-6-(methylcarbamoyl)phenyl)-1H-pyrazole-5-carboxamide (16a)
To a solution of 3-bromo-1-(3-chloropyridin-2-yl)-N-(2-methyl-6-(methylcarbamoyl)-4-
(methylsulfinyl)phenyl)-1H-pyrazole-5-carboxamide (15b, 30 mg, 0.0587 mmol) in dried CH2Cl2 (1 mL)
was added trifluoroacetamide (13.28 mg, 0.1175 mmol), magnesium oxide (9.46 mg, 0.2348 mmol),